Literature DB >> 9131222

The clinical spectrum of humidifier disease in synthetic fiber plants.

T M Pal1, J G de Monchy, J W Groothoff, D Post.   

Abstract

In a synthetic fiber production site with recirculating cold water humidification systems and small-size-particle (> 0.1 mu < 1 mu) oil mist exposure, humidifier disease was diagnosed in several workers. The patients could be divided into three groups illustrating the clinical spectrum of humidifier disease: humidifier fever (toxic inhalation fever) (12 patients): an asthma-like syndrome (8 patients); and allergic alveolitis (4 patients). Natural challenge at the work place, monitored by parameters such as peak-flow, spirometry, blood leucocyte count, and body temperature, provided important diagnostic information. In patients with chronic allergic alveolitis, a gradual recovery during an exposure-free period indicated a work-related causation, more than changes during challenge in normal work. In some patients, the fungus Sporothrix schenckii, hitherto unknown as a sensitizer, may have been at least one of the causative antigens. Measured levels of viable fungi (< or = 100 CFU/m3) and endotoxin (64 pg/m3) in air samples were much lower than those at which health effects usually are reported. Small-size-particle oil mist exposure may have underestimated the exposure to microorganisms, but otherwise an adjuvant role to this type of co-exposure might also be postulated. In contrast to allergic alveolitis, the asthma-like syndrome appeared to be more common in patients with a history of atopy and of smoking.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131222     DOI: 10.1002/(sici)1097-0274(199706)31:6<682::aid-ajim3>3.0.co;2-t

Source DB:  PubMed          Journal:  Am J Ind Med        ISSN: 0271-3586            Impact factor:   2.214


  3 in total

1.  Follow up investigation of workers in synthetic fibre plants with humidifier disease and work related asthma.

Authors:  T M Pal; J G de Monchy; J W Groothoff; D Post
Journal:  Occup Environ Med       Date:  1999-06       Impact factor: 4.402

Review 2.  A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases.

Authors:  Saumya Pandey; Satish K Srivastava; Kota V Ramana
Journal:  Expert Opin Investig Drugs       Date:  2012-01-28       Impact factor: 6.206

3.  Nasal PMN response to repeated challenge with endotoxin in healthy volunteers.

Authors:  Vinod Doreswamy; Neil E Alexis; Haibo Zhou; David B Peden
Journal:  Inhal Toxicol       Date:  2011-02       Impact factor: 2.724

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.